glp-1 data The trend: What the real-world reveals GLP-1 Receptor Agonist Market Size
Description
Early data are promising: retatrutide, a leading candidate in this class, produced 24.2% average weight loss at 48 weeks in a Phase 2 trial, exceeding results seen with current medications
gezonde voeding, regelmatige lichaamsbeweging en het koesteren van kostbare me-time
1395x: Definitions
A particular emphasis has been on the role of the incretin hormones of the gut (GLP-1 and GIP)
Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, et al
